Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity

Ch Latremouille, D. Genevaz, Ming C Hu, O. Schussler, N. Goussef, C. Mandet, P. Bruneval, N. Haeffner-Cavaillon, A. Carpentier, D. Glotz

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Xenotransplantation between discordant species leads to a hyperacute rejection mediated by natural antibodies, both of the IgG and IgM isotypes, activation of complement and endothelial cell activation. The combination of these mechanisms leads to a transplant survival of minutes to a few hours. Polyclonal human immunoglobulins for intravenous use (IVIg) from normal donors have proved effective in a number of antibody-mediated disorders, as well as in inflammatory disorders. We demonstrate that administration of IVIg in a guinea pig to rat model of cardiac xenografting can effectively delay hyperacute rejection. This effect is mediated by the F(ab')2 fragments of IVIg, and is correlated to an and-complementary activity.

Original languageEnglish (US)
Pages (from-to)122-126
Number of pages5
JournalClinical and Experimental Immunology
Volume110
Issue number1
DOIs
StatePublished - 1997

Keywords

  • Complement
  • IVIg
  • Xenotransplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity'. Together they form a unique fingerprint.

Cite this